Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy

Supportive Care in Cancer

Volumn 20, Issue 7, 2012, Pages 1525-1532

  Chan, Alexandre ^a,b   Chen, Christy ^a   Chiang, Joen ^b   Tan, Sze Huey ^b,c   Ng, Raymond ^b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c DUKE NUS MEDICAL SCHOOL   (Singapore)

Author keywords

Anthracycline; Breast cancer; Colony stimulating factors; Doxorubicin; Febrile neutropenia; G CSF

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; ASIAN; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CHINESE; COHORT ANALYSIS; COMORBIDITY; DISEASE PREDISPOSITION; DRUG DOSE REDUCTION; DRUG ERUPTION; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK POPULATION; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALAY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; RISK FACTOR; SINGAPORE; TREATMENT DURATION;

EID: 84984548108     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1241-6     Document Type: Article

References (21)

1. Budman DR, Berry DA, Cirrincione CT et al (1998) Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Canc Inst 90: 1205-1211
2. French Adjuvant Study Group (2001) Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year followup results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19: 602-611
3. Azim HA Jr, de Azambuja E, Colozza M et al. (2011) Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol (in press)
4. Gianni L, Norton L, Wolmark N et al (2009) Role of anthracyclines in the treatment of early breast cancer. J Clin Oncol 27: 4798-4808
5. Hortobagyi GN (1997) Anthracyclines in the treatment of cancer. An overview. Drugs 54 (Suppl 4): 1-7
6. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106: 2258-2266
7. National Comprehensive Cancer Network. Myeloid Growth Factors. In www.nccn.org/professionals/physician-gls/pdf/myeloid-growth.pdf (accessed 2010 Sept 1), Edition.
8. Smith TJ, Khatcheressian J, Lyman GH et al (2006) Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205
9. Wong AL, Chen J, Yap H et al. (2010) Correlation of ABCB1 and ABCC5 genetic variants with inter-ethnic differences in doxorubicin-induced hematologic toxicities. Proc Am Soc Clin Oncol 28: (abstr 138)
10. Chan A, Fu WH, Shih Vet al (2011) Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer 19: 497-504
11. Bonadonna G, Valagussa P, Moliterni A et al (1995) Adjuvant cyclophosphamide, methotrexate, and fluorouracil in nodepositive breast cancer: the results of 20 years of follow-up. N Engl J Med 332: 901-906
12. Leonard RC, Miles D, Thomas R, Nussey F (2003) Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 89: 2062-2068
13. Health Promotion Board, Singapore. Revision of Body Mass Index (BMI) Cut-offs in Singapore. In www.hpb.gov.sg/hpb/default.asp?TEMPORARY-DOCUMENT= 1769&TEMPORARY-TEMPLATE=2 (accessed 2011 Mar 1), Edition
14. Fisher B, Anderson S, Wickerham DL et al (1997) Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 15: 1858-1869
15. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23: 1178-1184
16. Timmer-Bonte JN, de Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23: 7974-7984
17. Minisini A, Spazzapan S, Crivellari D et al (2005) Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors. Crit Rev Oncol Hematol 53: 125-131
18. Jenkins P, Freeman S (2009) Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 20: 34-40
19. Lyman GH, Dale DC, Crawford J (2003) Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 21: 4524-4531
20. Barpe DR, Rosa DD, Froehlich PE (2010) Pharmacokinetic evaluation of doxorubicin plasma levels in normal and overweight patients with breast cancer and simulation of dose adjustment by different indexes of body mass. Eur J Pharm Sci 41: 458-463
21. Joerger M, Huitema AD, Richel DJ et al (2007) Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. Clin Pharmacokinet 46: 1051-1068